Next-Gen Biotech Platforms This slice is part of the broader Healthcare & Biotech theme.
Next-Gen Biotech Platforms names often move on drivers that differ from the rest of Healthcare & Biotech. Isolating this segment keeps earnings logic and news flow aligned with one part of the value chain.
Membership is based on Next Big Trend classification under Healthcare & Biotech → Next-Gen Biotech Platforms. Save the list as a watchlist to track updates without rebuilding Screener filters.
| Company | |||||||
|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $127.5B | -0.69% | -3.43% | +11.00% | +22.66% | 65 |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of | $58.7B | +3.70% | +1.70% | +18.79% | +28.08% | 79 |
| TEVA | Teva Pharmaceutical Industries Limited | $45.7B | -0.15% | +6.51% | +25.76% | +95.57% | 87 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $33.0B | -2.88% | -12.97% | -43.54% | -51.14% | 43 |
| RPRX | Royalty Pharma plc | $32.6B | -2.46% | -7.23% | +46.88% | +58.09% | 55 |
| ZTS | Zoetis Inc. | $30.2B | +5.76% | -0.31% | -41.01% | -47.83% | 72 |
| WST | West Pharmaceutical Services, Inc. | $25.6B | -0.48% | +7.81% | +32.34% | +37.01% | 88 |
| UTHR | United Therapeutics Corporation | $22.9B | -6.76% | +5.12% | +9.34% | +16.62% | 85 |
| JAZZ | Jazz Pharmaceuticals plc | $15.0B | -4.53% | -7.82% | +30.85% | +61.99% | 54 |
| ASND | Ascendis Pharma A/S | $14.7B | -2.03% | -14.62% | +4.43% | +6.11% | 39 |
| NBIX | Neurocrine Biosciences, Inc. | $14.6B | +0.38% | -8.95% | -0.41% | +3.10% | 51 |
| SMMT | Summit Therapeutics Inc. | $14.3B | +2.88% | -2.11% | -1.83% | -22.97% | 68 |
| BBIO | BridgeBio Pharma, Inc. | $13.0B | -2.79% | -14.51% | -14.97% | +19.96% | 39 |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | +2.71% | +2.28% | +63.21% | +66.37% | 80 |
| CORT | Corcept Therapeutics Incorporated | $12.6B | +3.96% | +2.45% | +240.63% | +164.75% | 80 |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | -6.07% | -14.78% | -7.64% | +0.35% | 38 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.5B | -4.56% | -12.76% | -18.10% | +9.31% | 44 |
| AXSM | Axsome Therapeutics, Inc. | $10.3B | -6.59% | -19.25% | -6.88% | +43.36% | 30 |
| KRYS | Krystal Biotech, Inc. | $9.6B | +0.61% | -5.97% | +32.76% | +78.83% | 58 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.4B | -6.25% | -26.49% | -8.51% | +66.23% | 20 |
| KYMR | Kymera Therapeutics, Inc. | $9.2B | -0.74% | -5.31% | +40.47% | +92.02% | 60 |
| PTGX | Protagonist Therapeutics, Inc. | $9.1B | +0.52% | -3.57% | +60.19% | +113.70% | 65 |
| TGTX | TG Therapeutics, Inc. | $8.1B | -0.52% | -2.40% | +78.93% | +46.14% | 67 |
| IONS | Ionis Pharmaceuticals, Inc. | $7.4B | -1.59% | -22.71% | -45.27% | -37.19% | 25 |
| SYRE | Spyre Therapeutics, Inc. | $7.0B | -11.15% | -8.09% | +143.90% | +398.75% | 53 |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.7B | -2.09% | +13.91% | +55.95% | +89.67% | 92 |
| IOVA | Iovance Biotherapeutics, Inc. | $6.7B | -6.47% | +57.89% | +387.55% | +510.55% | 98 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $6.2B | -4.04% | -11.30% | -16.26% | -10.21% | 46 |
| LGND | Ligand Pharmaceuticals Incorporated | $6.0B | -2.56% | +2.41% | +56.03% | +61.06% | 80 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | +4.69% | +0.29% | +90.91% | +106.58% | 74 |
| COGT | Cogent Biosciences, Inc. | $5.6B | -4.78% | -12.00% | -15.32% | -11.05% | 45 |
| ORKA | Oruka Therapeutics, Inc. | $5.6B | -7.36% | -15.54% | +154.97% | +275.69% | 37 |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.4B | -3.06% | -17.24% | +2.99% | +10.32% | 34 |
| PTCT | PTC Therapeutics, Inc. | $5.3B | -2.45% | -7.41% | -17.64% | -2.10% | 55 |
| DFTX | Definium Therapeutics, Inc. | $5.2B | -9.10% | -10.03% | +155.27% | +185.55% | 49 |
| MANE | Veradermics, Incorporated | $4.9B | +8.03% | +27.05% | +235.44% | — | 96 |
| TVTX | Travere Therapeutics, Inc. | $4.8B | -8.46% | -21.41% | +36.19% | +104.08% | 27 |
| DNTH | Dianthus Therapeutics, Inc. | $4.8B | -6.67% | -22.99% | +100.02% | +137.55% | 24 |
| ADPT | Adaptive Biotechnologies Corporation | $4.5B | -4.68% | +6.84% | +60.65% | +81.81% | 87 |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.4B | -1.56% | -29.26% | -26.69% | -9.10% | 15 |
| EWTX | Edgewise Therapeutics, Inc. | $4.3B | -3.09% | -9.59% | +58.09% | +159.11% | 50 |
| INDV | Indivior Pharmaceuticals, Inc. | $4.2B | +0.20% | +1.96% | -1.20% | +49.45% | 79 |
| RLAY | Relay Therapeutics, Inc. | $4.1B | -5.84% | -6.70% | +105.79% | +198.63% | 56 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.9B | -3.13% | -16.05% | +125.17% | +101.63% | 36 |
| TLX | Telix Pharmaceuticals Limited | $3.8B | +2.71% | -10.78% | +47.00% | +10.65% | 47 |
| LEGN | Legend Biotech Corporation | $3.8B | -3.16% | -6.03% | -13.94% | -40.43% | 57 |
| IDYA | IDEAYA Biosciences, Inc. | $3.7B | -4.63% | -5.97% | +4.31% | +33.95% | 58 |
| TNGX | Tango Therapeutics, Inc. | $3.7B | -7.69% | -5.96% | +154.74% | +209.60% | 58 |
| PLSE | Pulse Biosciences, Inc | $3.6B | +0.30% | -5.64% | +264.02% | +151.53% | 59 |
| VKTX | Viking Therapeutics, Inc. | $3.5B | -9.11% | -15.20% | -21.18% | -12.07% | 38 |
| XENE | Xenon Pharmaceuticals Inc. | $3.5B | -7.12% | -38.69% | -19.32% | -7.66% | 7 |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.4B | -4.29% | -12.75% | -11.80% | +5.55% | 44 |
| ELVN | Enliven Therapeutics, Inc. | $3.4B | -12.08% | -29.28% | +163.83% | +102.04% | 14 |
| DNLI | Denali Therapeutics Inc. | $3.4B | -9.06% | -13.44% | +13.08% | +25.30% | 42 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | -3.16% | +2.73% | -15.67% | +19.06% | 81 |
| RCUS | Arcus Biosciences, Inc. | $3.1B | -5.55% | -16.36% | 0.00% | +69.85% | 36 |
| DYN | Dyne Therapeutics, Inc. | $3.1B | +3.48% | -14.70% | -16.31% | +17.35% | 38 |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.8B | -12.00% | -6.71% | -39.40% | -34.00% | 56 |
| MBX | MBX Biosciences, Inc. | $2.7B | -5.84% | -15.46% | +68.83% | +227.49% | 37 |
| GRDN | Guardian Pharmacy Services, Inc. | $2.6B | +1.86% | -2.00% | +38.25% | +75.16% | 68 |
| BEAM | Beam Therapeutics Inc. | $2.5B | +0.86% | -2.28% | -11.26% | -2.11% | 67 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | -0.09% | +0.17% | -15.21% | -12.34% | 74 |
| RXRX | Recursion Pharmaceuticals, Inc. | $2.5B | -2.95% | +22.86% | -3.42% | -24.47% | 95 |
| CLDX | Celldex Therapeutics, Inc. | $2.4B | -8.95% | -24.45% | +7.88% | +11.75% | 22 |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | -4.84% | -15.42% | +17.08% | +125.94% | 37 |
| GPCR | Structure Therapeutics Inc. | $2.3B | -11.42% | -37.74% | -63.09% | -55.39% | 7 |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | +0.08% | -4.85% | +5.83% | +46.40% | 61 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.3B | -0.62% | -19.28% | +198.67% | +492.63% | 30 |
| AUPH | Aurinia Pharmaceuticals Inc | $2.2B | +1.69% | -0.18% | +1.69% | +38.51% | 73 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.2B | +2.09% | -5.85% | +6.28% | +19.28% | 58 |
| VERA | Vera Therapeutics, Inc. | $2.1B | -4.07% | -11.99% | -41.29% | -3.47% | 45 |
| ZBIO | Zenas BioPharma, Inc. | $2.1B | -6.08% | -18.74% | +50.10% | +161.40% | 31 |
| MLYS | Mineralys Therapeutics, Inc. | $2.1B | -5.65% | -26.62% | -38.33% | -40.57% | 19 |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | -3.42% | -19.31% | -41.07% | -12.67% | 30 |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | -1.72% | -7.83% | +17.27% | +59.03% | 53 |
| GENB | Generate Biomedicines, Inc. | $2.0B | +1.38% | -9.86% | +10.59% | — | 49 |
| LKFT | Lakefront Biotherapeutics | $1.9B | +2.25% | +7.58% | -9.76% | -15.52% | 88 |
| VIR | Vir Biotechnology, Inc. | $1.9B | -1.51% | +2.87% | +84.41% | +96.47% | 82 |
| TRVI | Trevi Therapeutics, Inc. | $1.9B | -9.56% | -22.93% | +2.44% | +34.29% | 24 |
| XERS | Xeris Biopharma Holdings, Inc. | $1.9B | +10.16% | +32.17% | +29.81% | +23.07% | 97 |
| SRPT | Sarepta Therapeutics, Inc. | $1.8B | +3.64% | -17.30% | -15.38% | -21.24% | 34 |
| PVLA | Palvella Therapeutics, Inc. | $1.8B | -1.05% | -13.22% | +25.48% | +85.72% | 42 |
| URGN | UroGen Pharma Ltd. | $1.8B | -8.80% | -17.82% | +57.90% | +119.60% | 33 |
| NTLA | Intellia Therapeutics, Inc. | $1.7B | +3.96% | +3.19% | +40.16% | -38.36% | 82 |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | -1.34% | +1.81% | -8.82% | -21.49% | 79 |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | +5.33% | -6.94% | +223.77% | +158.87% | 55 |
| STOK | Stoke Therapeutics, Inc. | $1.6B | -7.92% | -19.95% | -24.54% | -12.30% | 29 |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.5B | -7.24% | -14.82% | -19.56% | +2.74% | 38 |
| RAPP | Rapport Therapeutics, Inc. | $1.5B | -9.08% | -31.98% | -1.62% | +12.90% | 12 |
| NKTR | Nektar Therapeutics | $1.5B | -13.17% | -44.35% | -3.50% | -29.66% | 4 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | -42.24% | -43.91% | -16.95% | -13.46% | 4 |
| MAZE | Maze Therapeutics, Inc. | $1.5B | -2.89% | +5.29% | -37.53% | -7.11% | 85 |
| INBX | Inhibrx Biosciences, Inc. | $1.5B | -5.28% | -17.81% | +17.42% | +37.07% | 33 |
| AAPG | Ascentage Pharma Group International - American Depository Shares | $1.5B | -8.49% | -15.94% | -44.55% | -62.58% | 37 |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.4B | +3.66% | +6.85% | -33.52% | -48.59% | 87 |
| DRTS | Alpha Tau Medical Ltd. | $1.4B | -3.51% | -1.89% | +182.83% | +238.98% | 69 |
| TYRA | Tyra Biosciences, Inc. | $1.4B | -4.95% | -9.27% | -24.04% | +49.36% | 50 |
| OMER | Omeros Corporation | $1.4B | +3.52% | -1.39% | +11.29% | +330.63% | 70 |
| BCAX | Bicara Therapeutics Inc. | $1.3B | -5.16% | -26.99% | +2.55% | -5.01% | 18 |
| ORIC | Oric Pharmaceuticals, Inc. | $1.3B | -3.91% | -3.76% | +47.07% | -14.80% | 64 |
| DMRA | Damora Therapeutics, Inc. | $1.3B | +1.63% | -21.74% | -10.65% | +14.73% | 27 |
| PIII | P3 Health Partners Inc. | $1.3B | -15.31% | -36.94% | -45.69% | -78.98% | 8 |
| REPL | Replimune Group, Inc. | $1.2B | -3.05% | -9.76% | -2.28% | +2.76% | 49 |
| LBRX | LB Pharmaceuticals Inc | $1.2B | -7.16% | -27.40% | +55.48% | +116.18% | 18 |
| CSTL | Castle Biosciences, Inc. | $1.1B | -4.38% | +4.33% | -13.34% | +47.08% | 85 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.1B | +1.81% | +12.02% | -3.62% | -0.08% | 90 |
| JANX | Janux Therapeutics, Inc. | $1.1B | +9.08% | -4.29% | +34.06% | +74.74% | 62 |
| VOR | Vor Biopharma Inc. | $1.0B | +5.92% | -17.67% | +46.25% | +8.13% | 33 |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.0B | -8.35% | -27.63% | -34.18% | +39.84% | 17 |
| PCRX | Pacira BioSciences, Inc. | $986M | +45.50% | +40.61% | +40.61% | +54.06% | 97 |
| CRVS | Corvus Pharmaceuticals, Inc. | $977M | -6.59% | -23.41% | -50.14% | -44.12% | 24 |
| MLTX | MoonLake Immunotherapeutics | $971M | -7.76% | -22.89% | -19.73% | +14.01% | 24 |
| ABUS | Arbutus Biopharma Corporation | $961M | -8.33% | -19.15% | -13.10% | -2.56% | 31 |
| CGEM | Cullinan Therapeutics, Inc. | $953M | +6.40% | -27.45% | +49.37% | +164.73% | 17 |
| HELP | Helus Pharma Inc. | $898M | -9.99% | -21.64% | +31.05% | +76.61% | 27 |
| JBIO | Jade Biosciences, Inc. | $894M | +2.76% | -25.76% | -8.30% | +56.53% | 21 |
| PACB | Pacific Biosciences of California, Inc. | $892M | -8.37% | +78.29% | +22.99% | +64.29% | 99 |
| CADL | Candel Therapeutics, Inc. | $884M | -4.92% | -20.62% | +70.97% | +71.58% | 28 |
| RIGL | Rigel Pharmaceuticals, Inc. | $853M | +3.73% | +3.18% | +13.75% | +65.15% | 82 |
| SLBT | SL Science Holding Limited | $852M | -5.00% | -41.76% | -89.74% | -89.55% | 5 |
| AVTX | Avalo Therapeutics, Inc. | $843M | -10.17% | -26.25% | -26.05% | -0.37% | 20 |
| SGP | SpyGlass Pharma, Inc. | $829M | -7.09% | -10.47% | -6.74% | — | 48 |
| SANA | Sana Biotechnology, Inc. | $823M | -3.46% | -11.99% | -31.45% | -32.28% | 45 |
| LXRX | Lexicon Pharmaceuticals, Inc. | $810M | -3.30% | -18.14% | +53.04% | +15.79% | 33 |
| FDMT | 4D Molecular Therapeutics, Inc. | $800M | -8.24% | -10.44% | +69.33% | +52.64% | 48 |
| GYRE | Gyre Therapeutics, Inc. | $776M | -3.43% | -2.73% | -4.25% | -7.02% | 66 |
| ACRS | Aclaris Therapeutics, Inc. | $774M | -14.06% | -31.83% | +25.91% | +99.47% | 12 |
| DSGN | Design Therapeutics, Inc. | $774M | -6.13% | -23.50% | +22.49% | +77.04% | 23 |
| IMMX | Immix Biopharma, Inc. | $744M | -9.19% | -24.53% | +77.63% | +270.12% | 22 |
| SLDB | Solid Biosciences Inc. | $734M | -2.29% | -28.51% | +20.92% | +23.55% | 16 |
| CTKB | Cytek Biosciences, Inc. | $734M | -7.75% | +13.32% | +6.14% | +41.42% | 91 |
| FTH | Faeth Therapeutics, Inc. | $725M | -9.41% | -29.10% | -16.52% | -20.87% | 15 |
| OLMA | Olema Pharmaceuticals, Inc. | $722M | -5.44% | -24.52% | -68.72% | -25.10% | 22 |
| NVCT | Nuvectis Pharma, Inc. | $716M | -2.85% | -11.63% | +166.62% | +229.46% | 46 |
| OABI | OmniAb, Inc. | $715M | -6.61% | +16.06% | +151.89% | +182.42% | 93 |
| ZVRA | Zevra Therapeutics, Inc. | $701M | +8.06% | -8.64% | +22.77% | +7.95% | 51 |
| COLL | Collegium Pharmaceutical, Inc. | $698M | +1.24% | -5.35% | -52.25% | -33.78% | 59 |
| IRWD | Ironwood Pharmaceuticals, Inc. | $656M | +2.93% | -4.91% | +14.84% | +154.61% | 60 |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $640M | -17.11% | -45.82% | -50.17% | -45.56% | 3 |
| AURA | Aura Biosciences, Inc. | $638M | +7.70% | -9.65% | +19.36% | +12.93% | 49 |
| SGMT | Sagimet Biosciences Inc. - Series A | $621M | -4.80% | -17.86% | +50.68% | +21.53% | 33 |
| SLN | Silence Therapeutics Plc - American Depository Share | $610M | -11.11% | -29.74% | +56.58% | +85.21% | 14 |
| AQST | Aquestive Therapeutics, Inc. | $590M | +7.21% | -7.57% | -26.32% | -20.27% | 54 |
| CTMX | CytomX Therapeutics, Inc. | $588M | -6.08% | -30.23% | -42.02% | -25.83% | 13 |
| STTK | Shattuck Labs, Inc. | $568M | -17.25% | -10.58% | +55.07% | +131.02% | 48 |
| MPLT | MapLight Therapeutics, Inc. | $546M | -4.98% | -33.26% | +92.28% | — | 10 |
| EPRX | Eupraxia Pharmaceuticals Inc. | $542M | -3.32% | -8.24% | +0.26% | +26.69% | 53 |
| PHAT | Phathom Pharmaceuticals, Inc. | $542M | +0.71% | -17.76% | -57.02% | -34.23% | 33 |
| AGMB | AgomAb Therapeutics NV - ADRs representing one common share. | $530M | +6.59% | -38.37% | -37.06% | — | 7 |
| EOLS | Evolus, Inc. | $526M | +1.43% | -8.98% | +17.29% | +24.60% | 51 |
| MNPR | Monopar Therapeutics Inc. | $523M | +7.71% | -25.27% | +28.61% | -14.76% | 21 |
| CBIO | Crescent Biopharma, Inc. | $520M | -0.98% | -29.36% | +19.06% | +25.07% | 14 |
| NGNE | Neurogene Inc. | $513M | -0.19% | -30.04% | +28.64% | +12.91% | 14 |
| AUTL | Autolus Therapeutics plc | $508M | -4.32% | -12.81% | -11.06% | +18.79% | 44 |
| DRUG | Bright Minds Biosciences Inc. | $507M | +5.67% | -20.07% | -33.37% | +2.30% | 29 |
| MCTA | Charming Medical Limited | $504M | 0.00% | 0.00% | 0.00% | — | 74 |
| PBYI | Puma Biotechnology Inc | $499M | +1.32% | +10.17% | +67.56% | +92.47% | 90 |
| CAPR | Capricor Therapeutics, Inc. | $498M | -10.40% | -7.29% | -21.89% | -36.19% | 55 |
| ASMB | Assembly Biosciences, Inc. | $488M | -0.70% | -30.57% | -32.90% | -6.78% | 13 |
| CTNM | Contineum Therapeutics, Inc. | $473M | +1.46% | -12.95% | +15.31% | +18.95% | 43 |
| TKNO | Alpha Teknova, Inc. | $468M | -4.74% | +21.35% | +122.11% | +61.07% | 95 |
| ENTX | Entera Bio Ltd. | $466M | -13.49% | -11.97% | -32.61% | -28.95% | 45 |
| OVID | Ovid Therapeutics Inc. | $457M | -3.70% | -13.33% | +43.56% | +40.12% | 42 |
| DMAC | DiaMedica Therapeutics Inc. | $449M | -4.07% | +21.55% | +0.63% | +15.58% | 95 |
| TECX | Tectonic Therapeutic, Inc. | $444M | +0.35% | -25.36% | +9.06% | +52.58% | 21 |
| ZURA | Zura Bio Limited | $442M | -0.24% | -27.67% | -21.18% | +3.51% | 17 |
| SPRY | ARS Pharmaceuticals, Inc. | $434M | +10.68% | -12.81% | -60.86% | -55.86% | 43 |
| EIKN | Eikon Therapeutics, Inc. | $428M | +1.21% | -30.10% | -50.00% | — | 13 |
| AVIR | Atea Pharmaceuticals, Inc. | $415M | +1.08% | -2.18% | +44.40% | +77.15% | 68 |
| IRD | Opus Genetics, Inc. | $403M | -1.11% | -22.16% | +121.89% | +119.70% | 26 |
| GALT | Galectin Therapeutics Inc. | $394M | -3.19% | -10.12% | -12.50% | -23.69% | 49 |
| EDIT | Editas Medicine, Inc. | $385M | +12.70% | +2.53% | +38.54% | -27.74% | 80 |
| FENC | Fennec Pharmaceuticals Inc. | $379M | +2.90% | -8.76% | +38.05% | +12.13% | 51 |
| ARCT | Arcturus Therapeutics Holdings Inc. | $378M | -2.57% | -12.69% | +109.95% | +22.94% | 44 |
| ARTV | Artiva Biotherapeutics, Inc. | $377M | +0.15% | -36.98% | +58.51% | -43.97% | 8 |
| ENTA | Enanta Pharmaceuticals, Inc. | $367M | -5.76% | -8.61% | -23.27% | +9.21% | 52 |
| CCCC | C4 Therapeutics, Inc. | $367M | -9.24% | -17.15% | +49.21% | +25.00% | 35 |
| OBIO | Orchestra BioMed Holdings, Inc. | $362M | -9.76% | +5.14% | +38.07% | +109.89% | 85 |
| RLMD | Relmada Therapeutics, Inc. | $350M | -13.39% | -22.49% | -34.37% | +59.30% | 25 |
| TTRX | Turn Therapeutics Inc. | $346M | -14.43% | -17.16% | +189.09% | — | 35 |
| BNTC | Benitec Biopharma Inc. | $336M | -8.66% | -29.72% | -35.04% | -35.94% | 14 |
| LRMR | Larimar Therapeutics, Inc. | $318M | -11.76% | -30.23% | -29.13% | -42.80% | 13 |
| ABEO | Abeona Therapeutics Inc. | $316M | -1.00% | -15.21% | -5.88% | -7.12% | 38 |
| IPSC | Century Therapeutics, Inc. | $310M | -9.32% | -28.08% | +46.73% | +161.18% | 16 |
| INDP | Indaptus Therapeutics, Inc. | $306M | +11.79% | +13.94% | -62.11% | -65.43% | 92 |
| EVMN | Evommune, Inc. | $304M | -11.10% | -40.87% | -62.56% | — | 6 |
| PRLD | Prelude Therapeutics Incorporated | $300M | +2.37% | -23.77% | +33.79% | +509.31% | 23 |
| LXEO | Lexeo Therapeutics, Inc. | $297M | -11.33% | -28.35% | -67.67% | -61.51% | 16 |
| SRZN | Surrozen, Inc. | $296M | -6.77% | +39.64% | +23.76% | +103.42% | 97 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $293M | -3.65% | -33.95% | +85.93% | +61.94% | 10 |
| CATX | Perspective Therapeutics, Inc. | $288M | -0.37% | -9.36% | -1.45% | -21.90% | 50 |
| IKT | Inhibikase Therapeutics, Inc. | $287M | -1.04% | -20.75% | -6.83% | +17.90% | 28 |
| FATE | Fate Therapeutics, Inc. | $285M | -7.39% | -12.70% | +117.35% | +53.24% | 44 |
| CUVL | Clinuvel Pharmaceuticals Limited | $284M | -1.06% | -5.56% | -33.60% | -31.74% | 59 |
| FULC | Fulcrum Therapeutics, Inc. | $282M | +1.90% | -1.83% | -33.69% | -21.05% | 69 |
| XFOR | X4 Pharmaceuticals, Inc. | $277M | -1.41% | -22.50% | -30.25% | -18.90% | 25 |
| VNDA | Vanda Pharmaceuticals Inc. | $274M | -5.82% | -13.71% | -48.64% | -14.85% | 41 |
| ANIK | Anika Therapeutics Inc. | $273M | -0.67% | -7.90% | +100.10% | +107.67% | 53 |
| RCKT | Rocket Pharmaceuticals, Inc. | $272M | +1.54% | -27.55% | -25.07% | -16.24% | 17 |
| GLSI | Greenwich LifeSciences, Inc. | $270M | -12.74% | +0.73% | -27.94% | +34.82% | 76 |
| SABS | SAB Biotherapeutics, Inc. | $267M | -5.56% | -16.95% | -22.73% | +23.50% | 35 |
| IFRX | InflaRx N.V. | $265M | -10.53% | -26.79% | +51.49% | +10.87% | 19 |
| BCYC | Bicycle Therapeutics plc | $260M | +7.02% | -4.87% | -46.19% | -52.38% | 61 |
| AKBA | Akebia Therapeutics, Inc. | $258M | -6.45% | -14.58% | -49.39% | -72.38% | 39 |
| IVVD | Invivyd, Inc. | $256M | -14.22% | -12.15% | -71.64% | -57.03% | 45 |
| PALI | Palisade Bio, Inc. | $254M | +1.40% | -29.27% | -38.30% | -13.69% | 15 |
| NAUT | Nautilus Biotechnology, Inc. | $249M | +15.92% | +62.50% | -6.67% | +110.16% | 98 |
| LFCR | Lifecore Biomedical, Inc. | $248M | -1.53% | +57.21% | -21.39% | -4.60% | 98 |
| NNNN | Anbio Biotechnology | $244M | -26.55% | -28.59% | -84.64% | -84.32% | 16 |
| HITI | High Tide Inc. | $243M | -3.37% | +0.39% | -2.64% | -28.33% | 75 |
| STRO | Sutro Biopharma, Inc. | $243M | -4.07% | -16.54% | +32.41% | +82.38% | 36 |
| QTTB | Q32 Bio Inc. | $241M | -1.94% | -27.38% | -29.51% | -7.13% | 18 |
| CAMP | CAMP4 Therapeutics Corporation | $241M | -3.65% | -14.55% | -39.64% | +22.11% | 39 |
| PRQR | ProQR Therapeutics N.V. | $236M | -3.68% | -21.11% | -22.28% | -30.84% | 28 |
| SLGL | Sol-Gel Technologies Ltd. | $236M | -3.64% | +1.68% | +66.92% | +71.60% | 79 |
| LYEL | Lyell Immunopharma, Inc. | $231M | -6.59% | -31.75% | -71.44% | -50.31% | 12 |
| MGNX | MacroGenics, Inc. | $229M | -1.39% | -13.63% | +120.50% | +106.40% | 41 |
| LCTX | Lineage Cell Therapeutics, Inc. | $229M | +13.91% | 0.00% | -38.32% | -40.46% | 73 |
| CUE | Cue Biopharma, Inc. | $228M | -11.56% | -26.79% | +18.25% | -50.53% | 19 |
| KROS | Keros Therapeutics, Inc. | $223M | +3.37% | +2.92% | -42.83% | -25.62% | 82 |
| TRDA | Entrada Therapeutics, Inc. | $218M | -2.64% | -22.22% | -46.21% | -5.47% | 26 |
| PLX | Protalix BioTherapeutics, Inc. (DE) | $218M | +0.75% | +1.12% | +50.00% | +8.00% | 77 |
| SION | Sionna Therapeutics, Inc. | $215M | -3.92% | -34.49% | +35.09% | +94.26% | 10 |
| ELDN | Eledon Pharmaceuticals, Inc. | $215M | -0.62% | -14.18% | +60.26% | +76.43% | 40 |
| FOCL | EDAP TMS S.A. - American Depositary Shares, each representing One | $214M | -4.51% | -1.79% | +25.38% | +87.50% | 69 |
| FHTX | Foghorn Therapeutics Inc. | $209M | -31.85% | -57.39% | -63.15% | -54.98% | 2 |
| RNAC | Cartesian Therapeutics, Inc. | $204M | -5.54% | -21.52% | -5.41% | -29.98% | 27 |
| CMPX | Compass Therapeutics, Inc. | $203M | +9.13% | -54.89% | -48.54% | -23.45% | 2 |
| WHWK | Whitehawk Therapeutics, Inc. | $198M | -7.71% | -17.18% | +43.39% | +56.31% | 35 |
| NGEN | NervGen Pharma Corp. | $191M | -0.57% | -17.84% | -68.75% | -42.81% | 33 |
| BNR | Burning Rock Biotech Limited | $190M | -4.94% | +26.77% | -24.57% | +68.63% | 96 |
| ORMP | Oramed Pharmaceuticals Inc. | $186M | -6.25% | -12.13% | +58.08% | +81.66% | 45 |
| NKTX | Nkarta, Inc. | $184M | -13.28% | -23.71% | +20.00% | +7.77% | 23 |
| ANTX | AN2 Therapeutics, Inc. | $182M | -16.73% | -18.32% | +122.86% | +95.43% | 32 |
| IPHA | Innate Pharma S.A. | $182M | -6.92% | -27.80% | -15.43% | -25.10% | 17 |
| MSLE | Satellos Bioscience Inc. | $180M | -13.59% | -26.70% | +24.91% | +1.51% | 19 |
| MDWD | MediWound Ltd. | $176M | -8.68% | -10.26% | -32.72% | -29.87% | 49 |
| DTIL | Precision BioSciences, Inc. | $172M | +1.58% | -11.31% | +54.57% | +13.20% | 46 |
| ADCT | ADC Therapeutics SA | $167M | +47.22% | +30.33% | -54.96% | -63.11% | 96 |
| ABOS | Acumen Pharmaceuticals, Inc. | $167M | +1.45% | -26.32% | -0.47% | +21.39% | 20 |
| PEPG | PepGen Inc. | $163M | +7.69% | -24.44% | -63.44% | -51.53% | 23 |
| NBP | NovaBridge Biosciences | $157M | +2.24% | -19.41% | -65.58% | -68.51% | 30 |
| NERV | Minerva Neurosciences, Inc | $157M | -0.31% | -21.84% | -19.90% | +50.47% | 26 |
| MENS | Jyong Biotech Ltd. | $154M | +3.45% | -2.78% | -46.84% | -78.71% | 66 |
| VRXA | Veraxa Biotech AG | $154M | -8.40% | -31.45% | -77.04% | -76.58% | 12 |
| TARA | Protara Therapeutics, Inc. | $153M | -3.99% | -30.81% | -50.28% | -45.02% | 13 |
| MOLN | Molecular Partners AG | $151M | -2.56% | -12.41% | -12.59% | +2.70% | 45 |
| KZIA | Kazia Therapeutics Limited | $147M | -6.86% | -26.56% | +28.01% | +30.09% | 20 |
| VYGR | Voyager Therapeutics, Inc. | $146M | -11.40% | -27.08% | -39.69% | -49.89% | 18 |
| OTLK | Outlook Therapeutics, Inc. | $145M | -1.91% | -12.41% | -64.30% | -51.79% | 44 |
Companies classified under the Healthcare & Biotech theme and the Next-Gen Biotech Platforms sub-theme within Next Big Trend's catalog.
Yes. Signed-in users can save the current constituents from this page as a named watchlist.
No. It is a research universe for screening, not a recommendation.